Symbols / CANF $3.09 +1.98% Can-Fite BioPharma Ltd.
CANF Chart
About
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.25M |
| Enterprise Value | 4.51M | Income | -9.83M | Sales | 405.00K |
| Book/sh | 2.14 | Cash/sh | 1.99 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | inf | Forward P/E | -4.23 | PEG | — |
| P/S | 17.90 | P/B | 1.45 | P/C | — |
| EV/EBITDA | -0.46 | EV/Sales | 11.15 | Quick Ratio | 3.13 |
| Current Ratio | 3.46 | Debt/Eq | 1.27 | LT Debt/Eq | — |
| EPS (ttm) | -10.64 | EPS next Y | -0.73 | EPS Growth | — |
| Revenue Growth | -43.30% | Earnings | 2025-08-28 08:00 | ROA | -66.75% |
| ROE | -178.24% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -24.89% | Profit Margin | 0.00% | Shs Outstand | 2.14M |
| Shs Float | 4.28M | Short Float | 2.21% | Short Ratio | 0.02 |
| Short Interest | — | 52W High | 36.40 | 52W Low | 2.95 |
| Beta | -0.10 | Avg Volume | 720.53K | Volume | 3.38K |
| Target Price | $50.00 | Recom | Buy | Prev Close | $3.03 |
| Price | $3.09 | Change | 1.98% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$50.00
Mean price target
2. Current target
$3.08
Latest analyst target
3. DCF / Fair value
$-41.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.08
Low
$50.00
High
$50.00
Mean
$50.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-11-18 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-09-16 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-09-02 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-07-29 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-15 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-21 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-20 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-03 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-02-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-12-31 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-12-05 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-07-17 | init | EF Hutton | — → Buy | $10 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2023-10-24 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2023-06-02 | reit | HC Wainwright & Co. | — → Buy | $34 |
| 2023-03-13 | reit | HC Wainwright & Co. | — → Buy | $34 |
- CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Yahoo Finance hu, 05 Mar 2026 08
- Biotech Can-Fite unlocks $4M to fund drug R&D and clinical trials - Stock Titan Wed, 04 Mar 2026 08
- Why Did CANF Stock Soar 25% Today? - Stocktwits Wed, 04 Mar 2026 08
- Should I buy CanFite Biopharma (CANF) - Zacks Investment Research hu, 05 Mar 2026 08
- Can Fite Biopharma stock rises after patient success with liver treatment - Investing.com hu, 05 Feb 2026 08
- Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting - TipRanks ue, 10 Mar 2026 07
- Can-Fite (CANF) registers resale of 1,647,449 ADSs tied to repriced warrants - Stock Titan Fri, 03 Apr 2026 21
- Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split - Investing.com ue, 23 Dec 2025 08
- Can-Fite says liver cancer patient stayed cancer-free for more than 9 years - Stock Titan hu, 26 Mar 2026 07
- 118 dogs finish arthritis drug study as Can-Fite data nears - Stock Titan Mon, 30 Mar 2026 11
- Early trial finds pancreatic cancer drug from Can-Fite is well tolerated - Stock Titan Wed, 04 Mar 2026 08
- Pancreatic cancer drug Namodenoson hits trial milestone, eyes Q3 2026 data - Stock Titan ue, 20 Jan 2026 08
- Can-Fite obesity patent in Israel targets slice of $60.5B market - Stock Titan ue, 17 Mar 2026 07
- Brazil grants patent for a new way to tackle sexual dysfunction - Stock Titan Fri, 26 Dec 2025 08
- Biotech combines 3,000 shares into 1 in sweeping stock overhaul - Stock Titan ue, 23 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.41
-39.91%
|
0.67
-9.29%
|
0.74
-8.27%
|
0.81
|
| Operating Revenue |
|
0.41
-39.91%
|
0.67
-9.29%
|
0.74
-8.27%
|
0.81
|
| Operating Expense |
|
10.36
+17.62%
|
8.80
-1.50%
|
8.94
-18.05%
|
10.91
|
| Research And Development |
|
6.69
+16.26%
|
5.76
-3.78%
|
5.98
-22.93%
|
7.76
|
| Selling General And Administration |
|
3.66
+20.18%
|
3.05
+3.11%
|
2.96
-5.98%
|
3.14
|
| General And Administrative Expense |
|
3.66
+20.18%
|
3.05
+3.11%
|
2.96
-5.98%
|
3.14
|
| Other Gand A |
|
3.66
+20.18%
|
3.05
+3.11%
|
2.96
-5.98%
|
3.14
|
| Total Expenses |
|
10.36
+17.62%
|
8.80
-1.50%
|
8.94
-18.05%
|
10.91
|
| Operating Income |
|
-9.95
-22.39%
|
-8.13
+0.79%
|
-8.20
+18.83%
|
-10.10
|
| Total Operating Income As Reported |
|
-9.95
-22.39%
|
-8.13
+0.79%
|
-8.20
+18.83%
|
-10.10
|
| EBITDA |
|
-9.93
-22.20%
|
-8.12
+0.70%
|
-8.18
+18.87%
|
-10.08
|
| Normalized EBITDA |
|
-9.78
-20.78%
|
-8.10
+1.85%
|
-8.25
+15.82%
|
-9.80
|
| Reconciled Depreciation |
|
0.02
+242.86%
|
0.01
-53.33%
|
0.01
+7.14%
|
0.01
|
| EBIT |
|
-9.95
-22.39%
|
-8.13
+0.79%
|
-8.20
+18.83%
|
-10.10
|
| Total Unusual Items |
|
-0.15
-448.15%
|
-0.03
-139.13%
|
0.07
+124.38%
|
-0.28
|
| Total Unusual Items Excluding Goodwill |
|
-0.15
-448.15%
|
-0.03
-139.13%
|
0.07
+124.38%
|
-0.28
|
| Net Income |
|
-9.83
-24.72%
|
-7.88
-3.22%
|
-7.63
+24.96%
|
-10.17
|
| Pretax Income |
|
-9.83
-24.72%
|
-7.88
-3.22%
|
-7.63
+24.96%
|
-10.17
|
| Net Non Operating Interest Income Expense |
|
0.27
-2.53%
|
0.28
-43.70%
|
0.49
+138.83%
|
0.21
|
| Net Interest Income |
|
0.27
-2.53%
|
0.28
-43.70%
|
0.49
+138.83%
|
0.21
|
| Interest Income Non Operating |
|
0.28
-2.41%
|
0.29
-42.49%
|
0.51
+127.93%
|
0.22
|
| Interest Income |
|
0.28
-2.41%
|
0.29
-42.49%
|
0.51
+127.93%
|
0.22
|
| Other Income Expense |
|
-0.15
-448.15%
|
-0.03
-139.13%
|
0.07
+124.38%
|
-0.28
|
| Gain On Sale Of Security |
|
-0.15
-448.15%
|
-0.03
-139.13%
|
0.07
+124.38%
|
-0.28
|
| Tax Provision |
|
—
|
—
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-9.83
-24.72%
|
-7.88
-3.22%
|
-7.63
+24.96%
|
-10.17
|
| Net Income From Continuing Operation Net Minority Interest |
|
-9.83
-24.72%
|
-7.88
-3.22%
|
-7.63
+24.96%
|
-10.17
|
| Net Income From Continuing And Discontinued Operation |
|
-9.83
-24.72%
|
-7.88
-3.22%
|
-7.63
+24.96%
|
-10.17
|
| Net Income Continuous Operations |
|
-9.83
-24.72%
|
-7.88
-3.22%
|
-7.63
+24.96%
|
-10.17
|
| Normalized Income |
|
-9.68
-23.26%
|
-7.85
-1.95%
|
-7.70
+22.11%
|
-9.89
|
| Net Income Common Stockholders |
|
-9.83
-24.72%
|
-7.88
-3.22%
|
-7.63
+24.96%
|
-10.17
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
0.00
|
0.00
|
| Diluted EPS |
|
-10.75
+45.03%
|
-19.55
+39.40%
|
-32.26
+46.24%
|
-60.00
|
| Basic EPS |
|
-10.75
+45.03%
|
-19.55
+39.40%
|
-32.26
+46.24%
|
-60.00
|
| Basic Average Shares |
|
0.91
+126.97%
|
0.40
+70.22%
|
0.24
+74.12%
|
0.14
|
| Diluted Average Shares |
|
0.91
+126.97%
|
0.40
+70.22%
|
0.24
+74.12%
|
0.14
|
| Diluted NI Availto Com Stockholders |
|
-9.83
-24.72%
|
-7.88
-3.22%
|
-7.63
+24.96%
|
-10.17
|
| Total Other Finance Cost |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
-12.50%
|
0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
9.51
+4.32%
|
9.12
-8.70%
|
9.99
+7.61%
|
9.28
|
| Current Assets |
|
9.44
+5.10%
|
8.98
-9.35%
|
9.91
+8.20%
|
9.16
|
| Cash Cash Equivalents And Short Term Investments |
|
8.54
+8.28%
|
7.89
-11.60%
|
8.92
+11.71%
|
7.99
|
| Cash And Cash Equivalents |
|
5.53
+14.57%
|
4.83
+12.79%
|
4.28
+43.65%
|
2.98
|
| Other Short Term Investments |
|
3.01
-1.63%
|
3.06
-34.07%
|
4.64
-7.29%
|
5.01
|
| Receivables |
|
—
|
—
|
—
|
0.05
|
| Other Receivables |
|
—
|
—
|
—
|
0.05
|
| Prepaid Assets |
|
—
|
—
|
0.91
-19.15%
|
1.12
|
| Other Current Assets |
|
0.90
-17.81%
|
1.09
+11.05%
|
0.99
-15.73%
|
1.17
|
| Total Non Current Assets |
|
0.07
-46.38%
|
0.14
+70.37%
|
0.08
-35.71%
|
0.13
|
| Net PPE |
|
0.07
-46.38%
|
0.14
+70.37%
|
0.08
-35.71%
|
0.13
|
| Gross PPE |
|
0.09
-54.74%
|
0.19
-44.77%
|
0.34
-8.02%
|
0.37
|
| Accumulated Depreciation |
|
-0.01
+76.92%
|
-0.05
+80.23%
|
-0.26
-6.05%
|
-0.25
|
| Properties |
|
—
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.02
+13.33%
|
0.01
-94.42%
|
0.27
-10.03%
|
0.30
|
| Other Properties |
|
0.07
-60.57%
|
0.17
+182.26%
|
0.06
+0.00%
|
0.06
|
| Leases |
|
—
|
0.00
-100.00%
|
0.01
+0.00%
|
0.01
|
| Total Liabilities Net Minority Interest |
|
3.92
+6.46%
|
3.68
-1.66%
|
3.75
-22.14%
|
4.81
|
| Current Liabilities |
|
2.73
+33.09%
|
2.05
+1.58%
|
2.02
-19.26%
|
2.50
|
| Payables And Accrued Expenses |
|
1.46
+58.76%
|
0.92
+35.75%
|
0.68
-42.58%
|
1.18
|
| Payables |
|
1.16
+87.86%
|
0.62
+44.73%
|
0.43
-52.34%
|
0.90
|
| Accounts Payable |
|
1.16
+87.86%
|
0.62
+44.73%
|
0.43
-52.34%
|
0.90
|
| Current Accrued Expenses |
|
0.30
-1.00%
|
0.30
+20.40%
|
0.25
-11.66%
|
0.28
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.81
+20.15%
|
0.68
-2.74%
|
0.69
+41.06%
|
0.49
|
| Current Debt And Capital Lease Obligation |
|
0.06
+5.66%
|
0.05
+96.30%
|
0.03
-43.75%
|
0.05
|
| Current Capital Lease Obligation |
|
0.06
+5.66%
|
0.05
+96.30%
|
0.03
-43.75%
|
0.05
|
| Current Deferred Liabilities |
|
0.41
+0.00%
|
0.41
-34.89%
|
0.62
-20.56%
|
0.78
|
| Current Deferred Revenue |
|
0.41
+0.00%
|
0.41
-34.89%
|
0.62
-20.56%
|
0.78
|
| Total Non Current Liabilities Net Minority Interest |
|
1.19
-27.02%
|
1.63
-5.45%
|
1.73
-25.25%
|
2.31
|
| Long Term Debt And Capital Lease Obligation |
|
0.01
-70.59%
|
0.05
+292.31%
|
0.01
-7.14%
|
0.01
|
| Long Term Capital Lease Obligation |
|
0.01
-70.59%
|
0.05
+292.31%
|
0.01
-7.14%
|
0.01
|
| Non Current Deferred Liabilities |
|
1.18
-25.62%
|
1.58
-7.71%
|
1.71
-25.36%
|
2.29
|
| Non Current Deferred Revenue |
|
1.18
-25.62%
|
1.58
-7.71%
|
1.71
-25.36%
|
2.29
|
| Stockholders Equity |
|
5.59
+2.87%
|
5.44
-12.93%
|
6.24
+39.60%
|
4.47
|
| Common Stock Equity |
|
5.59
+2.87%
|
5.44
-12.93%
|
6.24
+39.60%
|
4.47
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
2.62
+163.32%
|
0.99
+119.38%
|
0.45
+66.70%
|
0.27
|
| Ordinary Shares Number |
|
2.62
+163.32%
|
0.99
+119.38%
|
0.45
+66.70%
|
0.27
|
| Additional Paid In Capital |
|
180.65
+5.85%
|
170.67
+4.32%
|
163.60
+6.10%
|
154.19
|
| Retained Earnings |
|
-176.19
-5.91%
|
-166.36
-4.97%
|
-158.48
-5.06%
|
-150.85
|
| Gains Losses Not Affecting Retained Earnings |
|
1.13
+0.00%
|
1.13
+0.00%
|
1.13
+0.00%
|
1.13
|
| Other Equity Adjustments |
|
1.13
+0.00%
|
1.13
+0.00%
|
1.13
+0.00%
|
1.13
|
| Total Equity Gross Minority Interest |
|
5.59
+2.87%
|
5.44
-12.93%
|
6.24
+39.60%
|
4.47
|
| Total Capitalization |
|
5.59
+2.87%
|
5.44
-12.93%
|
6.24
+39.60%
|
4.47
|
| Working Capital |
|
6.71
-3.19%
|
6.93
-12.15%
|
7.89
+18.53%
|
6.66
|
| Invested Capital |
|
5.59
+2.87%
|
5.44
-12.93%
|
6.24
+39.60%
|
4.47
|
| Total Debt |
|
0.07
-31.73%
|
0.10
+160.00%
|
0.04
-35.48%
|
0.06
|
| Capital Lease Obligations |
|
0.07
-31.73%
|
0.10
+160.00%
|
0.04
-35.48%
|
0.06
|
| Net Tangible Assets |
|
5.59
+2.87%
|
5.44
-12.93%
|
6.24
+39.60%
|
4.47
|
| Tangible Book Value |
|
5.59
+2.87%
|
5.44
-12.93%
|
6.24
+39.60%
|
4.47
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.95
-17.18%
|
-7.64
+9.51%
|
-8.44
+21.86%
|
-10.80
|
| Cash Flow From Continuing Operating Activities |
|
-8.95
-17.18%
|
-7.64
+9.51%
|
-8.44
+21.86%
|
-10.80
|
| Net Income From Continuing Operations |
|
-9.83
-24.72%
|
-7.88
-3.22%
|
-7.63
+24.96%
|
-10.17
|
| Depreciation Amortization Depletion |
|
0.02
+242.86%
|
0.01
-53.33%
|
0.01
+7.14%
|
0.01
|
| Depreciation |
|
0.02
+242.86%
|
0.01
-53.33%
|
0.01
+7.14%
|
0.01
|
| Depreciation And Amortization |
|
0.02
+242.86%
|
0.01
-53.33%
|
0.01
+7.14%
|
0.01
|
| Other Non Cash Items |
|
0.04
-60.00%
|
0.09
+140.54%
|
-0.22
-296.46%
|
0.11
|
| Stock Based Compensation |
|
0.34
-6.08%
|
0.36
+38.70%
|
0.26
-0.76%
|
0.26
|
| Asset Impairment Charge |
|
0.04
+13.51%
|
0.04
-60.64%
|
0.09
+74.07%
|
0.05
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
-71.43%
|
0.01
+227.27%
|
-0.01
-104.80%
|
0.23
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.43
+262.17%
|
-0.27
+71.69%
|
-0.94
+27.52%
|
-1.30
|
| Change In Prepaid Assets |
|
0.20
+278.90%
|
-0.11
-159.24%
|
0.18
+176.35%
|
-0.24
|
| Change In Payables And Accrued Expense |
|
0.68
+203.14%
|
0.22
+174.33%
|
-0.30
-59.57%
|
-0.19
|
| Change In Payable |
|
0.68
+203.14%
|
0.22
+174.33%
|
-0.30
-59.57%
|
-0.19
|
| Change In Account Payable |
|
0.54
+184.29%
|
0.19
+140.72%
|
-0.47
-708.62%
|
-0.06
|
| Change In Other Working Capital |
|
-0.41
-16.05%
|
-0.35
+53.03%
|
-0.74
+8.27%
|
-0.81
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
—
|
| Change In Other Current Liabilities |
|
-0.03
-3.13%
|
-0.03
+61.90%
|
-0.08
-35.48%
|
-0.06
|
| Investing Cash Flow |
|
-0.00
-100.13%
|
1.50
+200.20%
|
0.50
-94.76%
|
9.50
|
| Cash Flow From Continuing Investing Activities |
|
-0.00
-100.13%
|
1.50
+200.20%
|
0.50
-94.76%
|
9.50
|
| Net PPE Purchase And Sale |
|
-0.00
+60.00%
|
-0.01
-150.00%
|
-0.00
+77.78%
|
-0.01
|
| Purchase Of PPE |
|
-0.00
+60.00%
|
-0.01
-150.00%
|
-0.00
+77.78%
|
-0.01
|
| Capital Expenditure |
|
-0.00
+60.00%
|
-0.01
-150.00%
|
-0.00
+77.78%
|
-0.01
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
1.50
+200.00%
|
0.50
-94.74%
|
9.51
|
| Purchase Of Investment |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
9.64
+43.70%
|
6.71
-26.61%
|
9.14
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
9.64
+43.70%
|
6.71
-26.61%
|
9.14
|
0.00
|
| Net Common Stock Issuance |
|
9.64
+43.70%
|
6.71
-26.61%
|
9.14
|
0.00
|
| Changes In Cash |
|
0.69
+21.79%
|
0.57
-52.66%
|
1.20
+192.53%
|
-1.30
|
| Effect Of Exchange Rate Changes |
|
0.01
+145.45%
|
-0.02
-122.45%
|
0.10
+186.73%
|
-0.11
|
| Beginning Cash Position |
|
4.83
+12.79%
|
4.28
+43.65%
|
2.98
-32.16%
|
4.39
|
| End Cash Position |
|
5.53
+14.57%
|
4.83
+12.79%
|
4.28
+43.65%
|
2.98
|
| Free Cash Flow |
|
-8.95
-17.13%
|
-7.64
+9.48%
|
-8.44
+21.91%
|
-10.81
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.00
|
0.00
|
| Common Stock Issuance |
|
9.64
+43.70%
|
6.71
-26.61%
|
9.14
|
0.00
|
| Issuance Of Capital Stock |
|
9.64
+43.70%
|
6.71
-26.61%
|
9.14
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|